Novo Nordisk SG&A Expenses 2010-2024 | NVO

Novo Nordisk sg&a expenses for the twelve months ending December 31, 2024 were $9.770B, a 9.23% increase year-over-year.

  • Novo Nordisk annual sg&a expenses for 2024 were $9.77B, a 9.23% increase from 2023.
  • Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
  • Novo Nordisk annual sg&a expenses for 2022 were $7.177B, a 9.87% increase from 2021.

Novo Nordisk SG&A Expenses 2010-2024 | NVO

  • Novo Nordisk annual sg&a expenses for 2024 were $9.77B, a 9.23% increase from 2023.
  • Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
  • Novo Nordisk annual sg&a expenses for 2022 were $7.177B, a 9.87% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$827.9B
Johnson & Johnson (JNJ)$384.4B
AbbVie (ABBV)$354.6B
Roche Holding AG (RHHBY)$262.5B
Merck (MRK)$221.8B
Novartis AG (NVS)$219.3B
Pfizer (PFE)$146.8B
Sanofi (SNY)$137.4B
Bayer (BAYRY)$22.6B
Innoviva (INVA)$1.1B